title: B7H4, HSP27 and DJ-1 molecular markers as prognostic factors in pancreatic cancer.
abstract: OBJECTIVE
  Pancreatic cancer (PC) is one of the most lethal tumors of the gastrointestinal tract. The ability to predict which patients would benefit most from surgical intervention and chemotherapy would be a great clinical tool. A large number of potential markers have been identified lately in pancreatic cancer and their clinical utilities as prognostic tools are under investigation.
  
  
  METHODS
  We recruited 41 patients who had undergone radical surgical resection for PC between 2003 and 2010. To investigate the prognostic factors, we evaluated 3 possible markers: B7H4, HSP27 and DJ-1 protein expressions in the tissue specimens of these 41 patients by immunohistochemistry and analyzed the clinical and pathological features of these specimens.
  
  
  RESULTS
  The expression of the three antigens was independently associated with a negative impact of chemotherapy with gemcitabine on patient's survival. Moreover, patients who overexpressed B7H4 had worse prognosis than the ones who did not.
  
  
  CONCLUSIONS
  B7H4, DJ-1 and HSP27 may be used in the future as prognostic markers that express resistance of pancreatic cancer patients to chemotherapy with gemcitabine.
authors.affiliation: Department of Surgery, General Hospital 'Agios Dimitrios', Thessaloniki, Greece; 2nd Department of Surgery and Laboratory of Experimental Surgery, Faculty of Medicine, Democritus University of Thrace, Alexandroupolis, Greece. Electronic address: natasha_tsia@yahoo.com.
authors.forename: A
authors.initials: A
authors.lastname: Tsiaousidou
authors.forename: M
authors.initials: M
authors.lastname: Lambropoulou
authors.forename: E
authors.initials: E
authors.lastname: Chatzitheoklitos
authors.forename: G
authors.initials: G
authors.lastname: Tripsianis
authors.forename: C
authors.initials: C
authors.lastname: Tsompanidou
authors.forename: C
authors.initials: C
authors.lastname: Simopoulos
authors.forename: A K
authors.initials: AK
authors.lastname: Tsaroucha
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D055551:HSP27 Heat-Shock Proteins / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D047908:Intracellular Signaling Peptides and Proteins / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015513:Oncogene Proteins / Q000032:analysis*; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D011379:Prognosis; D000071617:Protein Deglycase DJ-1; D016019:Survival Analysis; D060907:V-Set Domain-Containing T-Cell Activation Inhibitor 1 / Q000032:analysis*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D055551:HSP27 Heat-Shock Proteins; D047908:Intracellular Signaling Peptides and Proteins; D015513:Oncogene Proteins; D060907:V-Set Domain-Containing T-Cell Activation Inhibitor 1; D003841:Deoxycytidine; C105131:PARK7 protein, human; D000071617:Protein Deglycase DJ-1; D000093542:Gemcitabine
keywords: Biomarkers; Chemotherapy resistance; Immunohistochemistry; Pancreatic cancer